{"filing":{"accession_number":"0001104659-26-065254","cik":"0001701541","ticker":"BDTX","company_name":"Black Diamond Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"tm2615293d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465926065254/tm2615293d1_8k.htm"},"events":[{"id":9348,"run_id":8201,"accession_number":"0001104659-26-065254","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Black Diamond Therapeutics announced positive Phase 2 clinical trial results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, demonstrating a preliminary median progression-free survival of 15.2 months, an objective response rate of 60%, and no new safety signals.","company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":955,"accession_number":"0001104659-26-065254","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses positive Phase 2 clinical trial results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations via press release under Item 7.01 (Regulation FD Disclosure). While this is material clinical development news that would affect investor assessment of the company's pipeline and prospects, it does not fit the earnings_release category (which typically covers financial results) nor any other specific event type in the taxonomy. Clinical trial results are a distinct category of material disclosure for biotech/pharma companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:34:06.727166+00:00","company_name":"","ticker":null,"filing_date":""},{"id":956,"accession_number":"0001104659-26-065254","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Black Diamond Therapeutics announced Phase 2 trial results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, showing a preliminary median progression-free survival of 15.2 months, ORR of 60%, and no new safety signals. While this is a clinical trial result disclosure, it does not fit the \"earnings_release\" category (which typically refers to financial results) and is material to investors evaluating the company's pipeline and development prospects. This is classified as \"other_material\" because it represents a significant clinical milestone for a biotech company's lead candidate that would affect investor assessment of the registrant's value and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:34:06.727166+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":955,"accession_number":"0001104659-26-065254","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses positive Phase 2 clinical trial results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations via press release under Item 7.01 (Regulation FD Disclosure). While this is material clinical development news that would affect investor assessment of the company's pipeline and prospects, it does not fit the earnings_release category (which typically covers financial results) nor any other specific event type in the taxonomy. Clinical trial results are a distinct category of material disclosure for biotech/pharma companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:34:06.727166+00:00","company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","filing_date":"2026-05-21"},{"id":956,"accession_number":"0001104659-26-065254","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Black Diamond Therapeutics announced Phase 2 trial results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, showing a preliminary median progression-free survival of 15.2 months, ORR of 60%, and no new safety signals. While this is a clinical trial result disclosure, it does not fit the \"earnings_release\" category (which typically refers to financial results) and is material to investors evaluating the company's pipeline and development prospects. This is classified as \"other_material\" because it represents a significant clinical milestone for a biotech company's lead candidate that would affect investor assessment of the registrant's value and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:34:06.727166+00:00","company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","filing_date":"2026-05-21"}]}